ANZAC: A Randomised Phase II Feasibility Study Investigating The Biological Effects of the Addition of Zoledronic Acid To Neoadjuvant Comnination Chemotherapy On Invasive Breast Cancer
Read time: 1 mins
Last updated:30th May 2007
The principle objective is to study the short-term biological effects of treatment and whether the addition of zoledronic acid to combination neoadjuvant (pre-operative) chemotherapy causes additive or synergistic efects on tumour growth ininvasive breast cancer; specifically assessing apoptosis (programmed cancer cell death) and proliferation (cancer activity). It is hoped the study will determine whether the addition of zoledronic acid to neoadjuvant chemotherapy causes an increase in apoptosis between the diagnostic core biopsy and an additional core biopsy for research purposes on day 5, compared to neoadjuvant chemotherapy alone.
|Study start date||2007-05-30|